Startups
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
Medigene at a glance:
- 1994: founded as a Munich Gene Center spin-off
- 2000: IPO, listed on the Frankfurt Stock Exchange
- 2001: acquisition of the US biotechnology company NeuroVir
- 2004: Acquisition of products and technology of Munich Biotech AG
- 2006: Acquisition of the British biotechnology company Avidex Limited
- 2014: Acquisition of Trianta Immunotherapies GmbH
- 2015: Medigene initiated first proprietary DC vaccine clinical trial
- 2016: Medigene’s DC trial entered phase II
- 2016: Medigene announced collaboration on first clinical TCR-T trial in Germany
- 2016: Medigene signed development partnership to develop and characterize new TCR-Ts for bluebird bio Inc. USA
- 2018: Start of the first, own clinical TCR-T trial with MDG1011
- 2018: Expansion of the bluebird bio partnership
- 2019: Medigene signed research and development partnership for innovative cellular therapies in Asia with Cytovant/Roivant
- Focus on T-cell-directed immunotherapies
- T cell receptor-modified T cell (TCR-T)-therapy MDG1011 for indications with high unmet medical need like AML, MM and MDS in clinical Phase I/II trial
- Dendritic cell vaccines (DCs) in ongoing clinical phase I/II trial
- Over 100 employees with expertise in immunotherapy and pharmaceutical development
- Headquartered in Martinsried near Munich (Germany), with US-office in San Diego, California
For further information please see our press releases, have a look at our annual and quarterly reports, or contact us by phone or e-mail.
Medigene at a glance:
- 1994: founded as a Munich Gene Center spin-off
- 2000: IPO, listed on the Frankfurt Stock Exchange
- 2001: acquisition of the US biotechnology company NeuroVir
- 2004: Acquisition of products and technology of Munich Biotech AG
- 2006: Acquisition of the British biotechnology company Avidex Limited
- 2014: Acquisition of Trianta Immunotherapies GmbH
- 2015: Medigene initiated first proprietary DC vaccine clinical trial
- 2016: Medigene’s DC trial entered phase II
- 2016: Medigene announced collaboration on first clinical TCR-T trial in Germany
- 2016: Medigene signed development partnership to develop and characterize new TCR-Ts for bluebird bio Inc. USA
- 2018: Start of the first, own clinical TCR-T trial with MDG1011
- 2018: Expansion of the bluebird bio partnership
- 2019: Medigene signed research and development partnership for innovative cellular therapies in Asia with Cytovant/Roivant
- Focus on T-cell-directed immunotherapies
- T cell receptor-modified T cell (TCR-T)-therapy MDG1011 for indications with high unmet medical need like AML, MM and MDS in clinical Phase I/II trial
- Dendritic cell vaccines (DCs) in ongoing clinical phase I/II trial
- Over 100 employees with expertise in immunotherapy and pharmaceutical development
- Headquartered in Martinsried near Munich (Germany), with US-office in San Diego, California
For further information please see our press releases, have a look at our annual and quarterly reports, or contact us by phone or e-mail.
Overview
Location
Germany, Bavaria, Planegg
Employees
51-200
Founded date
1994
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 26
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 25, 2025 | OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer | BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced th... |
| Aug 8, 2024 | WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers | Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispecific antibody platform WuXiBody™ Collabor... |
| Jun 25, 2024 | ArcticZymes Technologies Announces Nomination of Dr. Frank Mathias as Chairman of the Board | ArcticZymes Technologies Announces Nomination of Dr. Frank Mathias as Chairman of the Board Tue, Jun 25, 2024 08:26 CET Report this content Tromsø, Norway – June 25, 2024 – ArcticZymes Technologies (OSE:AZT) is pleased to announce the nomin... |
| Mar 6, 2024 | Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting | |
| Aug 17, 2023 | Medigene AG Reports Second Quarter and Six Months 2023 Financial Results and Provides Corporate Update | Pipeline expansion into neoantigens with multiple KRAS mutations as the first targets Acquired exclusive, worldwide rights to a CD40L-CD28 costimulatory switch protein Data from MDG1015 and multiple TCRs combined with PD1-41BB costimulatory... |
| Mar 29, 2023 | Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate Update | Continued progress in 2022 with corporate strategy update, end-to-end platform innovation, pipeline expansion, and acceleration of lead candidate development Partnering momentum continues with a $3 million milestone payment from 2seventy bi... |
| Jan 18, 2023 | Medigene Receives $3 Million Milestone Payment from 2seventy bio | |
| Feb 22, 2022 | BioNTech and Medigene co-develop T-cell receptor immunotherapies against cancer | The Mainz-based company BioNTech SE and the biotechnology company Medigene AG in Martinsried intend to jointly develop T-cell receptor-based immunotherapies for the treatment of cancer as part of a global collaboration. Under the terms of t... |
| Feb 3, 2022 | Medigene : reports preliminary efficacy and immune monitoring data of Phase I of Phase I/II MDG1011 trial in blood cancers | Planegg/Martinsried - * TCR-T immunotherapy MDG1011 is safe, well tolerated and shows clinical and biological activity in patients with late-stage blood cancers * One patient still under monitoring more than 6 months after treatment Martins... |
Show more
Reviews 0
FAQ about Medigene AG
When was Medigene AG founded?
Medigene AG was founded in 1994.
What has the press written about Medigene AG?
Parsers VC has collected 26 articles mentioning Medigene AG, among them “OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer” (Mar 25, 2025) and “WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers” (Aug 8, 2024).
Is Medigene AG still active?
Yes, Medigene AG is active; its latest activity on Parsers VC dates from May 28, 2026.